|
**Overview**: Malaria Vivax Falciparum Antigen Panel**Introduction**: The Malaria Vivax Falciparum Antigen Panel is a diagnostic tool designed to detect malaria antigens using whole blood samples. In India, malaria affects ~0.5-1 million cases annually (P. vivax ~50-60 percent, P. falciparum ~40-50 percent), with high transmission in tribal/rural areas (Odisha, Chhattisgarh, Northeast). High morbidity from under-testing leading to delayed ACT therapy, causing severe falciparum malaria (cerebral, renal failure) or vivax relapses. Per malaria practices aligned with NVBDCP and ICMR guidelines, the test employs antigen detection (HRP2 for falciparum, pLDH for vivax) over 1-2 days with high sensitivity/specificity, valuable for rapid diagnosis in endemic areas. This diagnostic falls under infection screening and targets patients with fever, chills, or travel to endemic zones, addressing accurate detection to guide artemisinin-based therapy and prevent complications. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise species identification and reducing malaria mortality. Its whole blood-based approach ensures reliable antigen detection.**Other Names**: Malaria Ag Pnl.**FDA Status**: FDA approved, CLIA certified for microbiology/hematology, compliant with 2025 standards.**Historical Milestone**: RDT antigen panel standard; in India, backbone of NVBDCP.**Purpose**: The test assesses 2 parameters including Plasmodium vivax antigen to guide malaria screening, detect vivax/falciparum, inform ACT therapy.**Test Parameters**: 1. Plasmodium Vivax Antigen, 2. Plasmodium Falciparum Antigen.**Pretest Condition**: No fasting required; patients should report fever or endemic exposure.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve antigen integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for antigen).**Medical History**: Patients should provide details on fever pattern, travel, prophylaxis.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated malaria including cerebral complications, benefits of rapid detection, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using antigen detection by trained personnel to ensure sterile technique and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low parasitemia can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive vivax/falciparum antigen confirms species, necessitating specialist input.**Specialist Consultation**: Infectious disease specialists should be consulted for management.**Additional Supporting Tests**: Microscopy, PCR for confirmation.**Test Limitations**: HRP2 deletion in some falciparum; comprehensive approach required.**References**: Indian Journal of Medical Microbiology 2024, Malaria Studies India 2023. |
